Which topical cream reduces time to clearance of molluscum contagiosum?

No Topical Cream Has Strong Evidence for Reducing Clearance Time of Molluscum Contagiosum

The most recent and highest quality evidence shows that molluscum contagiosum lesions typically resolve spontaneously in 6-12 months, and while several topical treatments have been studied, none have demonstrated consistent, clinically significant acceleration of clearance time that would justify routine use over physical removal methods.

Current Guideline Recommendations

The most recent guidelines 1 consistently state that treatment to remove lesions is indicated in symptomatic patients, with physical methods being the primary approach. Recommended physical removal options include:

• Incision and curettage (aggressive enough to cause bleeding)
• Simple excision
• Excision and cautery
• Cryotherapy

Importantly, guidelines explicitly note that molluscum lesions may spontaneously resolve but can persist for months to years 1, 2, 1.

Evidence on Topical Creams

Imiquimod 5% Cream - NOT Recommended

Multiple guidelines 3 specifically state that imiquimod was NOT shown to be of benefit compared with placebo in randomized controlled trials. While some observational studies and small trials showed partial responses 4, 5, 6, the FDA-requested randomized controlled trials definitively demonstrated lack of efficacy, though these remain unpublished 4.

Potassium Hydroxide 10% - Limited Evidence

Guidelines mention 10% potassium hydroxide as a treatment option 3, but note it has not proven highly successful. One comparative study showed similar efficacy to imiquimod (42% vs 44% complete clearance at 12 weeks), with faster onset but higher side effect rates 5.

Cantharidin - Inconsistent Results

Open-label studies suggest cantharidin may be effective 3, but in a small randomized controlled trial, improvement with cantharidin versus placebo was not statistically significant 3. A more recent 2018 trial 7 showed 36.2% clearance with cantharidin versus 10.6% with placebo (P=0.0065), but this represents modest benefit at best.

Berdazimer Gel (Zelsuvmi) - Recently FDA Approved

The FDA approved berdazimer gel 10.3% (Zelsuvmi) in January 2024 as the first prescription medication specifically for molluscum contagiosum 8. This nitric oxide-releasing topical is applied once daily for up to 12 weeks. Phase 3 trials (B-SIMPLE 2 and B-SIMPLE 4) demonstrated significant lesion reduction, though specific clearance rates and comparative efficacy data are not provided in the available evidence.

Other Topical Agents

• Acidified nitrite cream: One 1999 trial showed 75% cure rate versus 21% with control (P=0.01) 9, but this has not been validated in subsequent studies or incorporated into guidelines
• Podophyllotoxin, phenol, salicylic acid: Mentioned in systematic reviews 10 but lack robust evidence

Clinical Algorithm

For symptomatic patients requiring treatment:

1. First-line: Physical removal (curettage, cryotherapy, excision) - this provides immediate lesion elimination

   • Identify and treat all nascent lesions to reduce viral load and allow host immune response to clear residual virus 1, 2, 1

2. Consider berdazimer gel (Zelsuvmi) if:

   • Physical removal is refused or impractical
   • Multiple widespread lesions present
   • Patient/parent preference for at-home treatment
   • Apply once daily for up to 12 weeks 8

3. Watchful waiting is acceptable for:

   • Asymptomatic lesions
   • Immunocompetent patients
   • When risk of transmission is low
   • Expected spontaneous resolution in 6-12 months 3

Critical Caveats

• Conjunctivitis may require weeks to resolve even after lesion elimination 1, 2, 1
• In adults, large/multiple lesions with minimal inflammation may indicate immunocompromised state - requires further evaluation 1, 2, 1
• Common side effects of topical treatments include local irritation, burning, erythema, and staining 7, 9, 5
• No topical cream has been shown to reliably reduce clearance time to less than the natural 6-12 month course in high-quality studies

The evidence does not support routine use of topical creams to accelerate clearance time. Physical removal remains the most effective approach when treatment is desired, with the newly approved berdazimer gel representing the first FDA-approved topical option for patients preferring non-invasive treatment.